HomeCompareCLSD vs MO

CLSD vs MO: Dividend Comparison 2026

CLSD yields 487.80% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLSD wins by $50753.82M in total portfolio value
10 years
CLSD
CLSD
● Live price
487.80%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50753.89M
Annual income
$36,168,404,531.85
Full CLSD calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — CLSD vs MO

📍 CLSD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLSDMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLSD + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLSD pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLSD
Annual income on $10K today (after 15% tax)
$41,463.41/yr
After 10yr DRIP, annual income (after tax)
$30,743,143,852.07/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, CLSD beats the other by $30,743,119,228.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLSD + MO for your $10,000?

CLSD: 50%MO: 50%
100% MO50/50100% CLSD
Portfolio after 10yr
$25376.99M
Annual income
$18,084,216,750.20/yr
Blended yield
71.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

CLSD
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
Altman Z
-48.3
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLSD buys
0
MO buys
0
No recent congressional trades found for CLSD or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLSDMO
Forward yield487.80%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$50753.89M$77.7K
Annual income after 10y$36,168,404,531.85$28,968.54
Total dividends collected$49478.61M$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: CLSD vs MO ($10,000, DRIP)

YearCLSD PortfolioCLSD Income/yrMO PortfolioMO Income/yrGap
1← crossover$59,480$48,780.49$10,558$768.31+$48.9KCLSD
2$334,811$271,167.03$11,352$1,015.87+$323.5KCLSD
3$1,784,770$1,426,522.08$12,482$1,367.86+$1.77MCLSD
4$9,016,553$7,106,848.63$14,103$1,883.39+$9.00MCLSD
5$43,202,271$33,554,559.81$16,472$2,664.91+$43.19MCLSD
6$196,483,123$150,256,693.49$20,024$3,897.79+$196.46MCLSD
7$848,895,486$638,658,543.63$25,537$5,933.74+$848.87MCLSD
8$3,487,095,949$2,578,777,778.75$34,478$9,476.77+$3487.06MCLSD
9$13,631,297,985$9,900,105,319.66$49,776$16,022.63+$13631.25MCLSD
10$50,753,893,375$36,168,404,531.85$77,699$28,968.54+$50753.82MCLSD

CLSD vs MO: Complete Analysis 2026

CLSDStock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Full CLSD Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this CLSD vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLSD vs SCHDCLSD vs JEPICLSD vs OCLSD vs KOCLSD vs MAINCLSD vs PMCLSD vs BTICLSD vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.